The systemic treatment of advanced and metastatic bladder cancer.

[1]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[2]  P. Cooke,et al.  BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. , 2003, Oncology reports.

[3]  M. Hussain,et al.  Current understanding of the biology of advanced bladder cancer , 2003, Cancer.

[4]  N. James,et al.  Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder , 2003, British Journal of Cancer.

[5]  I. Tannock,et al.  The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. , 2002, The Lancet. Oncology.

[6]  N. James,et al.  Organ preservation strategies in bladder cancer , 2002, Expert review of anticancer therapy.

[7]  C. Sternberg,et al.  High-risk metastatic urothelial cancer: chances for cure? , 2002, Current opinion in urology.

[8]  R. Millikan,et al.  Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Terry L. Smith,et al.  Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Parmar,et al.  Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Hainsworth,et al.  Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Redman,et al.  Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Souhami,et al.  Clinical Oncology, 2nd edn , 2000, British Journal of Cancer.

[15]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Eastham,et al.  Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Cooke,et al.  Bcl‐2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy , 2000, BJU international.

[20]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Droller.  Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial , 1999, The Lancet.

[23]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[24]  M. Parmar,et al.  A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. , 1998, British Journal of Cancer.

[25]  S. Groshen,et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. , 1998, Journal of the National Cancer Institute.

[26]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .

[27]  E. Vokes,et al.  Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  I. Tannock,et al.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Dreicer,et al.  Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Stöckle,et al.  Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. , 1996, Urology.

[33]  G. Steinberg,et al.  Surgical therapy for locally advanced bladder cancer. , 1996, Seminars in oncology.

[34]  R. Wahlqvist,et al.  Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 , 1996 .

[35]  F. Freiha,et al.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, The Journal of urology.

[36]  E. Messing,et al.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. , 1995, Urology.

[37]  A. Ceribelli,et al.  Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Droz,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. , 1991, European journal of cancer.

[40]  M. Igawa,et al.  Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. , 1990, The Journal of urology.

[41]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[43]  M. Benson,et al.  Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. , 1989, Urology.

[44]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[45]  F. Freiha,et al.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[47]  Whitmore Wf.  Management of invasive bladder neoplasms. , 1983 .

[48]  Seematter Rj.  Systemic chemotherapy of bladder cancer , 1982 .

[49]  Michael C. Perry,et al.  American Society of Clinical Oncology educational book , 2003 .

[50]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[51]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.